semaglutide new england journal of medicine NEJM on X: "In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks Oral Semaglutide and Cardiovascular Outcomes

Studies so far have followed users for just two years, so its unclear whether the medications can keep the weight off long-term or if additional side effects will emerge later on

The hype is mostly justified by real science but theres also a meaningful gap between the topical cosmetic products you can buy over-the-counter and the injectable peptide therapy that requires a prescription

Genetic variants in peptide pathways (revealed by Precision Peptide Genetic Test) may influence your dose sensitivity or response profile, but storage stability is independent of genetics

This is rare

Different polyphenols molecules often act in different ways in our metabolism